Inovio Pharmaceuticals, Inc.

NASDAQ:INO

Biotechnology

Healthcare
$1.69 -0.90%

-$0.01 today

Market cap
$116.77M
Beta
1.49
P/E (TTM)
-8.9
EPS (TTM)
-$0.12
52W Low $1.03High $2.98

Volume 11.56M

Average 2.73M

INO Other Working Capital

Cash effect of changes in other operating assets and liabilities.

Inovio Pharmaceuticals, Inc.NASDAQ: INO

Other Working Capital · Q1 FY2026 · quarter ended Mar 2026

Other working capital turns positive

Q1 FY2026 other working capital was $346.41K, compared with -$501.06K a year earlier. Trailing-twelve-month other working capital was -$2.17M. Over 3 fiscal years it compounded at -32.4% a year.

Context

  • Other working capital amounted to 4278.5% of revenue in FY2025, up 4047.1 pp from a year earlier.
  • Other working capital increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly other working capital holds near $346.41K or moves back toward the trailing-twelve-month quarterly average of -$542.18K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$346.41K-54.8% QoQ
Last fiscal yearDec 2025
-$2.8M+454.7% YoY
LTMMar 2026
-$2.17M-37.3% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+169.1%——
1 year+454.7%——
3-year CAGR-32.4%——
5-year CAGR——
10-year CAGR——

Other Working Capital history

USD · from the cash flow

Latest · FY2025
(2.8M) USD
Year-over-year change
-454.7%

Other Working Capital vs competitors

How INO compares with its peers on the latest reported figures

  • INO's LTM Mar 2026 other working capital of $2.17M is the 8th largest of the 10 companies compared; the peer median is $4.04M.
  • Its year-over-year change of -37.3% is the 2nd highest of 10, against a peer median of -138.9%.
  • Over three fiscal years its annual growth of -32.4% compares with a peer median of +9.4%.
INO Competitors Peer median
Other Working Capital for INO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$75.89M -45.8%—412.0%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$20.07M +2771.2%+9.4%1749.8%
SPROSpero Therapeutics, Inc.LTM Mar 2026$12.54M -150.3%—22.9%
IRDOpus Genetics, Inc.LTM Mar 2026$5.88M -232.3%+192.8%49.1%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$4.04M -138.9%——
AGENAgenus Inc.LTM Mar 2026$3.8M -152.4%-31.7%3.1%
ACTUActuate Therapeutics IncLTM Mar 2026$3.05M -556.4%——
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$2.17M -37.3%-32.4%—
FATEFate Therapeutics, Inc.LTM Mar 2026$260K -97.1%—4.1%
SEERSeer, Inc.LTM Mar 2026$235K -73.3%—1.6%
Peer median (excluding INO) $4.04M-138.9%+9.4%22.9%

Competitors are the stored peer set for INO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(303.66M)(279.82M)(135.12M)(107.25M)(84.95M)
Depreciation & Amortization4.73M5.5M3.5M3.13M2.99M
Deferred Income Tax04.03M(32.05K)00
Stock-Based Compensation26.34M22.56M11.07M6.6M3.76M
Change in Working Capital50.35M19.83M(10.26M)(2.66M)(9.22M)
Accounts Receivables11.03M(3.71M)9.33M1.21M0
Inventory00000
Accounts Payables26.14M32.61M(45.99M)(3.37M)(6.42M)
Other Working Capital13.18M(9.07M)26.4M(504.04K)(2.8M)
Other Non-Cash Items6.53M11.69M6.47M(3.88M)(1.21M)
Operating Cash Flow(215.71M)(216.22M)(124.37M)(104.08M)(88.63M)
Capital Expenditures(1.23M)(969.15K)(320.9K)(487.83K)(285.7K)
Acquisitions (Net)0(2M)6.22M00
Purchases of Investments(348.95M)(248.53M)(203.48M)(54.14M)(4.95M)
Sales of Investments174.84M361.08M284.93M158.64M19.27M
Other Investing Activities00059.32K0
Investing Cash Flow(175.34M)109.59M87.36M104.07M14.04M
Debt Repayment000(16.42M)0
Common Stock Issued209.44M82.96M5.46M68.31M53.16M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.06M(1.11M)(466.65K)(420.8K)(110.78K)
Financing Cash Flow211.5M81.84M5M51.48M53.05M
Effect of Forex Changes(30.13K)(25.56K)(3.92K)32.4K0
Net Change in Cash(179.58M)(24.81M)(32.02M)51.5M(21.54M)
Free Cash Flow(216.94M)(217.18M)(124.69M)(104.56M)(88.92M)

Inovio Pharmaceuticals, Inc.

NASDAQ:INO

Intrinsic Alpha fair value

Locked

Current Price

$1.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.